Clinical trial
Carboplatin and Etoposide With or Without Oblimersen Sodium in Treating Patients…
NCT00042978 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00042978 |
|---|---|
| Title | Carboplatin and Etoposide With or Without Oblimersen Sodium in Treating Patients With Extensive Stage Small Cell Lung Cancer |
| Official title | A Randomized Phase II Study Of Carboplatin And Etoposide With Or Without G3139 (NSC #683428, IND #58842) In Patients With Extensive Stage Small Cell Lung Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Extensive Stage Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer |
| Intervention type | Biological, Drug |
| Interventions | oblimersen sodium, carboplatin, etoposide |
| Enrollment | 55 |
| Start date | Apr 1, 2003 |
| Primary completion | May 1, 2005 |
| First posted | Jan 27, 2003 |
| Last update posted | Jan 14, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: